23/06/2025 – AB Science today announced that a new study from an independent research team based in China presents new evidences showing that masitinib offers a promising new approach to treating Alzheimer’s disease Download PDF Post navigationPreviousPrevious post:AB Science announces issuance of a Canadian patent protecting the composition of matter of AB8939, including its use in the treatment of acute myeloid leukemia, with protection until 2036NextNext post:AB Science provides an update on the renegotiation of loan repayment terms with its financial creditorsRelated PostsAB Science announces the successful completion of a EUR 1.925 million private placementJuly 8, 2025Masitinib receives FDA and EMA authorization for confirmatory phase 3 trial in metastatic castrate-resistant prostate cancer, with biomarker-driven patient selection targeting population most likely to benefitJuly 4, 2025AB Science provides an update on the renegotiation of loan repayment terms with its financial creditorsJune 30, 2025AB Science announces issuance of a Canadian patent protecting the composition of matter of AB8939, including its use in the treatment of acute myeloid leukemia, with protection until 2036June 12, 2025AB Science announces EMA approval of Masivet shelf-life extension to 4 yearsJune 9, 2025AB Science announces the settlement delivery of its latest capital increase for €1.8 millionMay 23, 2025
Masitinib receives FDA and EMA authorization for confirmatory phase 3 trial in metastatic castrate-resistant prostate cancer, with biomarker-driven patient selection targeting population most likely to benefitJuly 4, 2025
AB Science provides an update on the renegotiation of loan repayment terms with its financial creditorsJune 30, 2025
AB Science announces issuance of a Canadian patent protecting the composition of matter of AB8939, including its use in the treatment of acute myeloid leukemia, with protection until 2036June 12, 2025
AB Science announces the settlement delivery of its latest capital increase for €1.8 millionMay 23, 2025
